RAS mutation status and bortezomib therapy for relapsed multiple myeloma

British Journal of Haematology

Volumn 169, Issue 6, 2015, Pages 905-908

  Smith, Dean ^a   Armenteros, Elena ^b   Percy, Laura ^a   Kumar, Madhu ^b   Lach, Anna ^a   Herledan, Gaelle ^a   Stubbs, Matthew ^a   Downward, Julian ^b   Yong, Kwee ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b London Research Institute   (United Kingdom)

Author keywords

Bortezomib; Multiple myeloma; Prognosis; RAS mutation

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PHARMACOGENOMICS; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; GENETICS; MORTALITY; MUTATION; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; GENES, RAS; HUMANS; MULTIPLE MYELOMA; MUTATION; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TREATMENT OUTCOME;

EID: 84930276936     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13258     Document Type: Article

References (10)

1. Chng, W.J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S.V., Oken, M.M., Kyle, R.A., Henderson, K.J., van Wier, S., Greipp, P., van Ness, B. & Fonseca, R. (2008) Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia, 22, 2280-2284.
2. Dimopoulos, M.A., Beksac, M., Benboubker, L., Roddie, H., Allietta, N., Broer, E., Couturier, C., Mazier, M.A., Angermund, R. & Facon, T. (2013) Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica, 98, 1264-1272.
3. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V.; International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
4. Kropff, M., Bisping, G., Schuck, E., Liebisch, P., Lang, N., Hentrich, M., Dechow, T., Kroger, N., Salwender, H., Metzner, B., Sezer, O., Engelhardt, M., Wolf, H.H., Einsele, H., Volpert, S., Heinecke, A., Berdel, W.E., Kienast, J.; Deutsche Studiengruppe Multiples Myelom. (2007) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 138, 330-337.
5. Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N.E., Greipp, P., Kyle, R.A., Oken, M.M. & van Ness, B. (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88, 2699-2706.
6. Ludwig, H., Miguel, J.S., Dimopoulos, M.A., Palumbo, A., Garcia Sanz, R., Powles, R., Lentzsch, S., Ming Chen, W., Hou, J., Jurczyszyn, A., Romeril, K., Hajek, R., Terpos, E., Shimizu, K., Joshua, D., Hungria, V., Rodriguez Morales, A., Ben-Yehuda, D., Sondergeld, P., Zamagni, E. & Durie, B. (2014) International Myeloma Working Group recommendations for global myeloma care. Leukemia, 28, 981-992.
7. Mulligan, G., Lichter, D.I., Di Bacco, A., Blakemore, S.J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., Chattopadhyay, N., Bolen, J.B., Dorner, A.J., Van De Velde, H., Ricci, D., Jagannath, S., Berenson, J.R., Richardson, P.G., Stadtmauer, E.A., Orlowski, R.Z., Lonial, S., Anderson, K.C., Sonneveld, P., San Miguel, J.F., Esseltine, D.L. & Schu, M. (2014) Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood, 123, 632-639.
8. NICE 2014. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. April 2014 ed. http://www.nice.org.uk/guidance/TA311. Last accessed March 2014.
9. Steckel, M., Molina-Arcas, M., Weigelt, B., Marani, M., Warne, P.H., Kuznetsov, H., Kelly, G., Saunders, B., Howell, M., Downward, J. & Hancock, D.C. (2012) Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Research, 22, 1227-1245.
10. Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., Ashworth, A., Davies, F.E. & Morgan, G.J. (2012) Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood, 120, 1077-1086.